Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Collaboration leverages Remix’s REMaster platform for the discovery and development of small molecule therapies that modulate RNA processing.
February 18, 2022
By: Kristin Brooks
Managing Editor, Contract Pharma
Remix Therapeutics, an RNA-focused company launched over a year ago developing its REMaster drug discovery platform, has entered a strategic small molecule discovery and development collaboration with Janssen Pharmaceutica N.V., a division of Johnson & Johnson. The collaboration leverages Remix’s REMaster platform for the discovery and development of small molecule therapies that modulate RNA processing. While the collaboration details have not been disclosed, Janssen will have exclusive rights to three specific targets with applications in immunology and oncology. The companies did not disclose targets or indications for the small molecules being developed. Remix Chief Executive Officer Peter Smith said, “This collaboration further validates the therapeutic potential of our proprietary REMaster drug discovery platform.” He added that the funds from the collaboration will provide Remix with the additional resources necessary to continue to develop the company’s own pipeline of potential therapeutic candidates.” According to the company, the REMaster platform is stabilized by three legs; data analytics, bespoke high-throughput screening technologies and next-generation chemistry. This approach allows the company to precisely identify and target RNA processing steps in order to enhance or eliminate protein function or correct dysregulation in disease. Remix will receive an initial payment of $45 million in cash. The company is also eligible for preclinical, clinical, commercial and sales milestone payments. For any assets discovered and developed, Remix is eligible for royalties. Remix is designing therapeutics that target RNA processing in order to “fine-tune” how new RNA sequences are produced. The company’s small molecule technology can correct mutations at all of the RNA levels. Those small molecules are designed to be taken orally, which will allow therapeutic modulation throughout the body, including the central nervous system. By targeting RNA processing, there is the potential to address a broad range of diseases, including cancers, rare diseases and those of the central nervous system.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !